无容量
医学
易普利姆玛
内科学
荟萃分析
不利影响
随机对照试验
肿瘤科
相对风险
腹泻
癌症
作者
Shweta Kamat,Jay Patel,Britny R. Brown,Ami Vyas
标识
DOI:10.1080/07357907.2022.2108827
摘要
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
科研通智能强力驱动
Strongly Powered by AbleSci AI